YD Bio Limited
YDES
YD Bio Limited is a biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Its current portfolio includes DNA methylation-based cancer detection programs, ophthalmologic products, stem cell- and exosome-based therapeutics, and clinical trial drug supply services. The company also works in blood-based oncology testing, early cancer detection, treatment monitoring, and recurrence tracking, while serving pharmaceutical and biotechnology partners with compliant distribution and clinical trial support. Based in Taipei, Taiwan, YD Bio Limited operates as an integrated healthcare platform spanning diagnostics, regenerative medicine, eye care, and related commercial healthcare markets.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$597K
▲ +16.9% YoY
Net Income (TTM)
-$8M
▼ -488.8% YoY
Op. Margin
-882.74%
▼ -596.2pp YoY
ROIC
-125.75%
▼ -91.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▼ -94.4% YoY
Op. Cash Flow (TTM)
-$7M
▼ -439.5% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$6M
Continue Research
Peers
Biotechnology · Pick stocks to compare with YDES
Held by ETFs
YDES is in 1 US ETF. The largest of them, with YDES's weight in each:
YD Bio (YDES) in four numbers
Questions about YD Bio
Is YD Bio (YDES) overvalued?
At $4.83, YD Bio's price is 29524% above the $0.02 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is YD Bio's fair value?
Intrinsiqq's calculator puts YD Bio's fair value at $0.02 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 2.3, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.01. Every input can be changed on the Intrinsic Value tab.
Is YD Bio a high-quality business?
YD Bio scores 25 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from company filings. Its best check is revenue growth at 30.6%, and its weakest is return on capital at -125.8%. The Quality tab shows every check against its target.
Does YD Bio (YDES) pay a dividend?
No. YD Bio (YDES) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing YDES
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.